Centocor, Inc., a Johnson & Johnson company, has expanded its earlier license and option agreement to use Vical‘s Incorporated naked DNA technology to develop and commercialize certain DNA vaccines for the potential treatment of some types of cancer.
Vical will receive an undisclosed upfront payment and could receive additional milestone payments in the future.
The agreement does not change Vical’s forecast for a net loss of between $28 million and $32 million for 2002.
Vical Incorporated is focused on the development of pharmaceutical product candidates based on its patented gene delivery technology.
A number of therapeutic and vaccine product candidates are currently under development for the prevention or treatment of cancer, infectious diseases and metabolic disorders by Vical and its collaborative partners.